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Myosin-Binding protein-C (MyBP-C) is a family of accessory proteins of striated muscles that contributes to the assembly and
stabilization of thick ﬁlaments, and regulates the formation of actomyosin cross-bridges, via direct interactions with both thick
myosin and thin actin ﬁlaments. Three distinct MyBP-C isoforms have been characterized; cardiac, slow skeletal, and fast skeletal.
Numerous mutationsin thegene forcardiac MyBP-C(cMyBP-C)have been associated with familial hypertrophic cardiomyopathy
(FHC) and have led to increased interest in the regulation and roles of the cardiac isoform. This review will summarize our current
knowledge on MyBP-C and its role in modulating contractility, focusing on its interactions with both myosin and actin ﬁlaments
in cardiac and skeletal muscles.
1.Introduction
Striated muscle cells contain a complex, highly ordered
cytoskeleton, mainly composed of interdigitating thick
myosin and thin actin ﬁlaments [1]. Muscle contraction
and relaxation occurs by the sliding of myosin ﬁlaments
past actin ﬁlaments under the strict regulation of their
accessory proteins, which are responsible for their assembly
and maintenance as well as the regulation of contractile
activity [1].
Myosin-Bindingprotein-C(MyBP-C)comprisesafamily
of accessory proteins of the thick myosin ﬁlaments that
encompasses ∼2% of the total myoﬁbrillar protein [2]. To
date, two major roles have been attributed to MyBP-C; it
contributes to the regular organization and stabilization of
thickﬁlamentsandmodulatestheformationofcross-bridges
between myosin and actin, via direct interactions with both
ﬁlamentous systems (as reviewed in [3, 4]). Within the
sarcomere,MyBP-ClocalizestotheC-zone,thecross-bridges
containing region of the A-band, in 7–9 transverse stripes
that are ∼43nm apart [5–7].
Three MyBP-C isoforms have been identiﬁed; cardiac,
slow skeletal, and fast skeletal (cMyBP-C, sMyBP-C, and
fMyBP-C), encoded by diﬀerent genes localizing to human
chromosomes 11, 12, and 19, respectively [8, 9]. The core
structure of MyBP-C is composed of seven immunoglobulin
(Ig) domains and three ﬁbronectin type III (Fn-III) repeats,
numbered from the NH2-terminus as C1–C10 (Figure 1;
[10]). A proline/alanine- (pro/ala-) rich motif and a con-
served linker region, termed MyBP-C or M-motif, ﬂank the
ﬁrst Ig domain, C1. Notably, both the cardiac and slow
isoforms diﬀer slightly from the core structure. cMyBP-
C possesses three unique features, including an additional
Ig domain at the extreme NH2-terminus (termed C0), a
9-residue long insertion within the M-motif containing
consensus phosphorylation sites and a 28-amino acid long
loop in the middle of domain C5 [8, 11]. Conversely, sMyBP-
C comprises a subfamily of four alternatively spliced variants
(v), v1–v4, diﬀering from one another due to the retention
or exclusion of select exons encoding three novel insertions
[12]. These are located at the very NH2-terminus within the
pro/ala- rich motif, the middle of domain C7, and the very
COOH-terminus of the molecule, following the C10 domain
(Figure 1;[ 12]). The presence of these insertions may result
in diﬀerent topographies and possibly functions of the
sMyBP-C variants that contain them [12, 13]. Consistent
with this, v1, which carries the COOH-terminal insertion
preferentially localizes to the periphery of the M-band,2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of the three MyBP-C isoforms. White and light grey ovals represent immunoglobulin and ﬁbronectin
type-III domains, respectively. The M-motif, ﬂanked by domains C1 and C2 is denoted as a thick black line. Insertions speciﬁc to the cardiac
isoform and slow variants are shown as dark grey rectangles.
rather than the C-zone, where it codistributes with its
binding partners obscurin [13] and titin (our unpublished
observations) and plays key roles in the structural integrity
of M- and A-bands. The last Ig domain (C10) of sMyBP-
C v1 interacts with the second Ig domain (Ig2) of obscurin
[13]. Although the presence of the novel COOH-terminal
insertion further strengthens this interaction, it is not
required for binding. However, this novel motif is both
necessary and suﬃcient to support binding of sMyBP-C v1
to the last Ig domain of titin, M10, which is a hotspot for
mutations associated with tibial muscular dystrophy [14,
15]. Moreover, our laboratory has recently identiﬁed novel
phosphorylation sites within the pro/ala- rich motif of the
NH2-terminus of sMyBP-C, speciﬁcally Ser-59, located in
the novel NH2-terminal insertion and Ser-62 are targets of
PKA, while Ser-83 and Thr-84 are targets of PKC; Ser-204 is
a substrate for both PKA and PKC [16]. Similar to its cardiac
counterpart, phosphorylation of these sites may be essential
in regulating the activities of sMyBP-C. Nevertheless, despite
the diﬀerences in the core structure of the cardiac, slow, and
fast MyBP-C proteins, they share a ∼50% homology and a
∼65% identity [12].
AlthoughMyBP-Cwasidentiﬁedoverfortyyearsagoasa
contaminant of puriﬁed myosin [17], a better understanding
of its physiology has emerged in the last two decades,
parallelingthediscoveryofmutationsincMyBP-Cthatresult
in the development of familial hypertrophic cardiomyopathy
(FHC; [18, 19]). Consequently, most of our knowledge
originates from studies focusing on the cardiac form of the
protein. This review will focus on the role of MyBP-C in
regulating the formation of actomyosin cross-bridges via its
direct interaction with both myosin and actin ﬁlaments.
2. Interactions of cMyBP-C with
the Myosin Filament
Myosin is a hexameric protein consisting of two heavy chains
(MHC) and two light chains (regulatory and essential, RLC
and ELC, resp.). A dimer of heavy chains forms a coiled-
coil helix that constitutes the rod or light meromyosin
(LMM) segment of myosin [20]. Toward its NH2-terminus,
the helix unwinds and each MHC gives rise to a catalytic
head, referred to as subfragment 1 (S1) that has ATPase
activity and participates in the formation of cross-bridges
with ﬁlamentous actin [21, 22]. The lever arm, referred to
as subfragment 2 (S2), separates the S1 segment from the
rod portion, and transduces the chemical energy from the
hydrolysis of ATP into mechanical movement along the thin
ﬁlament [23]. A pair of RLC and ELC binds in tandem to
each head of the S1 segment modulating the speed and force
of contraction [24, 25].
In addition to myosin light chains and actin, myosin is
intimately associated with MyBP-C (Table 1 and Figure 2;
[26]). The COOH-terminal C10 domain of all three MyBP-
C isoforms harbors binding sites for the LMM portion of
myosin [27]. Charged residues R1064, E1079, N1083, R1100,
and R1101 present on the surface of the C10 domain of
MyBP-C support an electrostatic interaction with residues
1554–1581 of the rod domain of myosin that has a modest
aﬃnityof∼3.5μM[28,29].Moreover,throughdomainsC8–
C10, MyBP-C interacts with titin, a giant sarcomeric protein
spanning half a sarcomere, which is also tightly bound to the
thickmyosinﬁlament[30].Speciﬁcally,MyBP-Cbindstothe
ﬁrst Ig domain of an 11-domain superrepeat present in the
A-band portion of titin [31]. Thus, it has been speculatedJournal of Biomedicine and Biotechnology 3
Table 1: Ligands of the cardiac isoform of MyBP-C.
Cardiac MyBP-C
MyBP-C Domain Ligand Method Aﬃnity Reference
C0 Myosin RLC NMR, ITC 3.2μM[ 32]
C1 Myosin S1-S2 hinge region NMR [33]
M-motif Myosin S2 Cosedimentation assay, ITC 4.3μM[ 34]
C2 Myosin S2 ITC, NMR 1.1mM [35]
C10 Myosin LMM Cosedimentation 3.5μM[ 28, 29, 36]
C0 F-actin Co-IP, cosedimentation [37]
C0 and C1 F-actin Small angle neutron scattering [38]
C0–C2 F-actin Negative staining electron
microscopy [39]
C1-C2 F-actin Cosedimentation 10μM[ 40]
M-motif F-actin Cosedimentation [41]
C5–C10 F-actin Cosedimentation 4.3μM[ 42]
C5 MyBP-C C8 Y2H, SPR 10μM[ 43]
C7 MyBP-C C10 Y2H [43]
C8–C10 Titin C-Zone 11-repeat super repeat Dot-blot [31]
Abbreviations used: RLC, regulatory light chain; NMR, nuclear magnetic resonance; ITC, isothermal calorimetry; LMM, light meromyosin; Co-IP,
coimmunoprecipitation; Y2H, yeast 2 hybrid; SPR, surface plasmon resonance.
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Figure 2: Schematic representation of cardiac MyBP-C, illustrating its domain architecture and known binding partners. Immunoglobulin
and ﬁbronectin type III domains are shown as white and grey ovals, respectively. The M-motif is denoted as a dark black line ﬂanked by
domains C1 and C2. The cardiac speciﬁc insertion within domain C5 is shown as a grey rectangle. Ligands for cMyBP-C are indicated at
their sites of interaction.
that the repetitive binding of MyBP-C to the A-band portion
of titin likely contributes to its periodicity within the C-
zone [31]. Consistent with these ﬁndings, a number of
studieshavefurthershownthattheCOOH-terminalC8–C10
domains are necessary and suﬃc i e n tt ot a r g e tM y B P - Ct ot h e
A-band [44, 45].
While binding of the COOH-terminus of MyBP-C to the
r o dd o m a i no fm y o s i nm a yc o n t r i b u t et ot h em a i n t e n a n c e
and stability of the thick ﬁlament, (reviewed in [3, 4]),
binding of the NH2-terminus of MyBP-C to myosin may
mediate contractile regulation [3, 4]. Accordingly, a number
of biochemical and structural studies have implicated the
NH2-terminalportionofcMyBP-C,containingdomainsC0–
C2, in binding to the S2 region of myosin. Speciﬁcally,
the M-motif located between the C1 and C2 Ig domains
has been shown to bind directly to the NH2-terminal 126
residues of the S2 fragment with an aﬃnity of ∼4.3μM
[34]; this interaction is abolished by phosphorylation of
speciﬁc Ser residues within the M-motif of cMyBP-C via
cAMP-dependent protein kinase [46–49]. Similarly, the C2
domain has been also shown to interact with the same 126
residues of the NH2-terminus of the S2 fragment, albeit with
considerably lower aﬃnity (∼1.1mM), compared to the M-
motif [35]. Interestingly, molecular modeling has suggested
that the interaction between the S2 portion of myosin and
the C2 domain of cMyBP-C is mediated by polar residues
[35]. On the other hand, the C1 domain of cMyBP-C has
been reported to interact with the hinge region between the
S1 heads and the S2 fragment [33], in close proximity to the
myosin light chains, while a recent study reported that the
ﬁrst Ig domain of cMyBP-C, C0, binds to the RLCs with an
aﬃnity of ∼3.2μM[ 32]. In support of this, overexpressed
C0 targets to the A-band independently of the rest of the
molecule, likely through its interaction with the RLCs [32].
Taken together, these ﬁndings strongly suggest that
cMyBP-C may regulate the position and thus proximity of4 Journal of Biomedicine and Biotechnology
the myosin S1 heads relative to the actin ﬁlament, through
its interaction with the S2 region and the RLCs, therefore
aﬀecting the formation of actomyosin cross-bridges.
3. Interactionsof cMyBP-C with
the Actin Filament
Inadditiontothemountingexperimentalsupportindicating
the intimate association of the NH2-terminus of cMyBP-
C with the S2 region of myosin, there is also signiﬁcant
evidence supporting its direct interaction with actin thin
ﬁlaments. Early studies have shown that puriﬁed full-length
cMyBP-C binds to ﬁlamentous actin (F-actin) [36, 50].
However,reconstitutedthinﬁlaments(i.e.preincubatedwith
troponin and tropomyosin) fail to bind puriﬁed full length
cMyBP-C in the presence of EDTA, a Ca2+ chelating agent,
but binding is restored upon addition of Ca2+ [36, 50].
Further studies have recently begun to identify the actin-
binding domain(s) of cMyBP-C through biochemical and
structural approaches. Neutron scattering experiments have
indicated that recombinant C0–C2 binds to F-actin in a
repetitive manner, stabilizing it [38], while biochemical
studies have shown that recombinant C0 is capable of
directly interacting with F-actin [37]. Moreover, bacterially
expressed C1-C2 associates with naked F-actin as well as
reconstituted thin ﬁlaments, likely through the M-motif,
exhibiting a binding aﬃnity of ∼10μMt on a k e dF - a c t i n
[40, 41]. This ﬁnding has been also substantiated by a
recentstudythatusednegativestainelectronmicroscopyand
three-dimensional reconstruction to show that bacterially
expressed C0–C3 is well ordered on actin ﬁlaments near
subdomain 1 [51].
Noticeably, some of the above studies report linear,
nonsaturating binding, suggesting the presence of weak
electrostatic interactions, as exempliﬁed by the calculated
micromolar aﬃnity [41]. Consistent with this, these binding
reactions depend largely on pH and ionic strength and are
regulated by phosphorylation of cMyBP-C [42]. Thus, an
increase in pH or ionic strength signiﬁcantly decreases the
capacity of the aforementioned cMyBP-C peptides to bind
to F-actin [40–42]. Similarly, pretreatment of these recom-
binant peptides with PKA results in a dramatic reduction of
their ability to associate with F-actin [41].
Importantly, a recent study by Rybakova and colleagues
investigatedtheactin-bindingcapabilitiesofcMyBP-Cacross
its entire length [42]. In support of previously published
studies discussed above, the authors found that the NH2-
terminal domains of cMyBP-C bind to F-actin in a linear,
nonsaturating manner, likely mediated by weak electrostatic
interactions. However, recombinant full-length cMyBP-C,
expressed in the baculovirus system, supported a direct and
saturating interaction with F-actin with a calculated KD
of ∼4.3μM. Moreover, constructs lacking domains C0–C5
exhibited similar binding properties as full-length cMyBP-C
[42]; this observation prompted the authors to conclude that
the weak actin binding mediated by the NH2-terminus of
the molecule does not contribute signiﬁcantly to the overall
aﬃnity of cMyBP-C for F-actin. Moreover, the authors
further showed that the actin binding supported by the
COOH-terminal C6–C10 domains, unlike the NH2-terminal
C0–C2 domains, is independent of the regulatory elements,
troponin and tropomyosin, of thin ﬁlaments, the levels of
Ca2+, and the phosphorylation status of the M-motif [42].
AlthoughtheCOOH-terminusofcMyBP-Cexhibitsahigher
aﬃnity for F-actin, the minimal binding region and its phys-
i o l o g i c a lr e l e v a n c ea r es t i l le l u s i v e .T h e s eo p e nq u e s t i o n sa r e
especially important because the COOH-terminal domains
C6–C10 also harbor binding sites for myosin and titin
ﬁlaments (discussed above). Indeed, space constraints would
favor dynamic rather than simultaneous interactions of the
COOH-terminus of cMyBP-C with the actin, myosin, and
titin ﬁlaments. However, three-dimensional reconstruction
of thick ﬁlaments demonstrated that domains C7–C10 of
cMyBP-C run along the length of the myosin rod [52],
suggesting that its interaction with the LMM portion of
myosin is not of dynamic nature.
Collectively these studies suggest the presence of various
but weak binding sites for F-actin in the NH2-terminus of
c M y B P - Ca sw e l la st h ep r e s e n c eo fah i g ha ﬃnity, saturat-
ing binding site in the COOH-terminus of the molecule.
Obviously, more work is required before we can obtain a
clear understanding of the physiological relevance of these
interactions during muscle contraction and relaxation.
4. Interactionsof Myosin and Actin Filaments
withSkeletal MuscleMyBP-C
Early work has shown that the skeletal isoforms of MyBP-
C also interact directly with both thick and thin ﬁlaments;
however, their binding is much less characterized (Figure 3
and Table 2). Similar to cMyBP-C, the skeletal isoforms bind
to the rod portion of sarcomeric myosin through their C10
domain and to the S2 region through their NH2-terminus
[27]. Further characterization of the NH2-terminal binding
has shown that the ﬁrst two Ig domains of sMyBP-C (C1-C2)
bind to the S2 region with an aﬃnity of ∼2.2μM[ 26, 34].
In addition, native skeletal MyBP-C (presumably containing
a mixture of the slow and fast isoforms) coaggregates with
F-actin in a Ca2+ sensitive manner [50].
It becomes apparent from the above studies that our
knowledge on the interaction of slow or fast MyBP-C with
myosin and actin ﬁlaments is limited. There are several
reasons for this. The identiﬁcation of multiple mutations
in the cardiac isoform that have been causally linked to
the development of FHC is a major contributing factor
that has shifted the interest of researchers towards cMyBP-
C; however, this has recently changed, as mutations in
sMyBP-C were identiﬁed in patients suﬀering from distal
arthrogryposis type 1 (DA1), a disorder characterized by
congenital contractures of the hands and feet ([53]; please
see below). More importantly, the molecular diversity of the
skeletal isoforms further complicates the relevant studies as
there are at least ﬁve diﬀerent skeletal forms of MyBP-C
(one fast and four slow variants) that share homologous or
common sequences, contain novel insertions in the NH2-
and COOH-termini, and may coexist in the same muscle,Journal of Biomedicine and Biotechnology 5
Table 2: Ligands of the skeletal isoforms of MyBP-C.
Skeletal MyBP-C
MyBP-C Domain Ligand Method Aﬃnity Reference
C1-C2 Myosin S2 Cosedimentation assay, ITC 2.2μM[ 26, 34]
fast C10 Myosin ﬁlaments Cosedimentation assay 0.5μM[ 27]
Full length F-actin Cosedimentation [36, 50]
Full length Titin 11-domain super repeat Dot-blot [31, 54]
slow variant 1
C10 + insert Obscurin Ig2 Y2H, pull down, overlay [13]
slow variant 1
C10 + insert FHL1 Y2H, pull down, Co-IP [55]
Abbreviations used: RLC, regulatory light chain; NMR, nuclear magnetic resonance; ITC, isothermal calorimetry; LMM, light meromyosin; Co-IP,
coimmunoprecipitation; Y2H, yeast 2 hybrid; SPR, surface plasmon resonance.
Skeletal MyBP-C
F-actin
and
A-band titin
Obscurin Ig2
and
FHL1
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
Myosin LMM Myosin S2
Figure 3: Schematic representation of the core structure of the skeletal isoforms of MyBP-C, depicting their identiﬁed binding partners.
For ease of representation, the three novel insertions present in MyBP-C slow are not included in the schematic (for detailed description,
please see Figure 1 and [12]). Immunoglobulin and ﬁbronectin type III domains are presented as white and grey ovals, respectively. The
M-motif is shown as a dark black line ﬂanked by domains C1 and C2. Ligands for skeletal MyBP-C are denoted at their sites of interaction.
Notably,obscurinandFHL1arespeciﬁcbindingpartnersofv1,sincetheirinteractionsdependonthepresenceofthenovelCOOH-terminal
insertion, which is exclusively carried by v1, in addition to the C10 domain.
ﬁber, or even sarcomere [12]. Further detailed investigation
is, therefore, necessary to evaluate the ability of each isoform
to bind to myosin and actin ﬁlaments as well as the
physiological signiﬁcance of these interactions.
5.MyBP-CinDisease
During the last decade, an overwhelming number of
mutations (∼200) have been identiﬁed in the MYBPC3
gene, which encodes the human cardiac MyBP-C protein.
These include missense, nonsense, deletion/insertion, and
frame-shift mutations and have been causally linked to the
development of modest and late onset familial hypertrophic
cardiomyopathy (FCH) [56–58]. The majority of the non-
sense and frame-shift mutations result in truncated forms
of the protein, that lack the COOH-terminus harboring
binding sites for LMM, actin and titin, and thus negate
the ability of cMyBP-C to associate with these ﬁlaments
and regulate contractile activity [59]. Interestingly, these
truncated peptides are often undetectable in patient biop-
sies, possibly due to transcriptional misregulation or rapid
degradation [60]. Contrary to non-sense and frame shift
mutations, missense mutations are generally associated with
a less severe cardiomyopathic phenotype [58] and do not
aﬀect the structure or stability of the protein although some
of them have been suggested to weaken myosin binding [33].
Moreover, recent genome wide linkage analysis revealed
that mutations in the MYBPC1 gene that encodes the human
skeletal MyBP-C slow protein lead to the development
of distal arthrogryposis type 1, an autosomal dominant
disorder characterized by congenital contractures of the
hands and feet [53]. Two missense mutations have been
identiﬁed to date, W236R and Y856H, which are present in
the M-motif and C8 domain, respectively [53]. Evaluation of
skeletal muscle biopsies obtained from aﬀected individuals
revealed that slow twitch ﬁbers were signiﬁcantly smaller
than fast twitch ﬁbers. Importantly, the locations of these
two mutations indicate possible alterations in the ability
of sMyBP-C to interact with myosin or actin via its NH2-
terminus and to associate with the thick and titin ﬁlaments
through its COOH-terminus.
ThecausalinvolvementoftheMyBP-Cfamilyofproteins
in the development of cardiac and skeletal myopathies, as
exempliﬁed by the aforementioned studies, clearly indicates
thatthemembersofthismultifacetedandcomplexfamilyare
essential components and key regulators of muscle structure
and function.
6. The Regulatory Activitiesof
MyBP-C-Models andPerspectives
Through its dynamic interactions with myosin and actin
ﬁlaments,MyBP-Caﬀectstheformationandcyclingofcross-
bridges in three distinct ways: (i) by maintaining the normal
structure of myosin and actin ﬁlaments, (ii) by regulating
the rate at which myosin and actin interact, and (iii) by6 Journal of Biomedicine and Biotechnology
modulating the ATPase activity of myosin. Consistent with
this, the addition of skeletal MyBP-C reduces the critical
concentration necessary for myosin polymerization in vitro
and results in the formation of longer and more uniform
thick ﬁlaments [61, 62]. In addition, the NH2-terminal
region C0–C2 of cMyBP-C supports actin bundling in vitro,
as evidenced by the increased turbidity of F-actin in the
solution and the formation of signiﬁcantly thicker actin
ﬁlaments,asvisualizedbyelectronmicroscopy[41].Notably,
the eﬀect of cMyBP-C on actin bundling is dependent on pH
and regulated by phosphorylation events mediated by PKA
[41].Moreover,invitromotilityassays,examiningthesliding
of actin ﬁlaments over myosin heads in the presence of full-
length or truncated forms of cMyBP-C revealed a signiﬁcant
reduction in their sliding velocity [40, 63, 64]. Notably, the
degree of reduction was also dependent on the presence of
the actin regulatory proteins, troponin, and tropomyosin;
in their presence, there was a lesser eﬀect on the decrease
of actin motility over full-length myosin [63, 65], HMM
[40]o rS 1h e a d s[ 64]. MyBP-C also modulates the ATPase
activityofmyosin,thoughinanindirectway,viainteractions
with both myosin and actin ﬁlaments supported by its
NH2-terminus. In agreement with this, puriﬁed sMyBP-
C inhibited the ATPase activity of actin-activated myosin;
however, native cMyBP-C moderately enhanced the actin-
activated ATPase activity of myosin [66, 67]. Surprisingly
though,recombinantcMyBP-CcontainingtheC0–C2region
inhibited the ATPase activity of myosin in the presence of
actin [40].
The majority of the aforementioned studies have been
performed with native proteins obtained from diﬀerent
species or types of muscles, presumably due to ease of
puriﬁcation. However, Alyonycheva et al. have convincingly
shown that the strength of the interaction between myosin
and MyBP-C is considerably increased when both proteins
are puriﬁed from the same source [68]. As such, cMyBP-C
and skeletal MyBP-C bound with higher aﬃnity to cardiac
and skeletal myosin, respectively [68].
As our knowledge about the molecular and functional
properties of MyBP-C broadens, it becomes apparent that
through interactions supported by its COOH and NH2
termini, MyBP-C contributes to the maintenance of the
normal structure of thick ﬁlaments, and the regulation of
cross-bridges formation and cycling. It has, therefore, been
suggested that MyBP-C may serve as a linker, whereby its
COOH-terminus is necessary for anchoring it to LMM in
the A-band, leaving the NH2-terminus available to modulate
contractility through dynamic interactions with the head
region of myosin and actin [4]. Consequently, Calaghan
and colleagues proposed the “tether model” to explain how
MyBP-C modulates the formation of actomyosin cross-
bridges [69]. This model suggests that both myosin binding
sites on MyBP-C act together by limiting the movement of
the S1 heads relative to LMM and actin, thereby restricting
the formation of actomyosin cross-bridges [69]. Phosphory-
lation of select Ser residues within the M-motif of cMyBP-C,
mediated mainly by PKA, regulates the interaction between
cMyBP-C and myosin by acting as an “on-oﬀ”s w i t c h .
Consequently, when in the “on” or dephosphorylated state,
theNH2-terminusofcMyBP-Cbindstomyosinandlimitsits
interaction with actin, when in the “oﬀ” or phosphorylated
state, myosin is free to interact with actin and form cross-
bridges [70].
The tether model is centered on the dynamic and
highly regulated interaction of MyBP-C with myosin and
actin ﬁlaments. However, it is necessary to understand the
orientation of MyBP-C within the sarcomere, as well. Two
proposed models for the topology of MyBP-C have been
suggested: a “collar model” in which a trimer of MyBP-C
molecules wraps around the rod domain of myosin [43],
andan“axialmodel”,wheretheCOOH-terminusofMyBP-C
runs along the length of the rod domain [71]. A stipulation
of the collar model is that MyBP-C is required to dimerize
[43]. In support of this, it has been shown that MyBP-C
dimerizes through interactions mediated by domains C5 and
C7 with C8 and C10, respectively [43, 72]. On the other
hand, X-ray diﬀraction in combination with molecular and
computational modeling studies support the axial model,
suggesting that the last three domains of MyBP-C lay along
the length of the myosin rod [71, 73]. Recently, a study using
electron microscopy and three-dimensional reconstructions
of cardiac thick ﬁlaments further demonstrated that the
COOH-terminus of cMyBP-C runs along the rod domain
surface of thick ﬁlaments [52]. Although MyBP-C dimeriza-
tion is not essential for the arrangement of MyBP-C along
the length of the myosin rod, the axial model does not negate
its dimerization. Nevertheless, in both models the NH2-
terminus of MyBP-C extends into the interﬁlament space
where it is accessible to bind to the S2 portion of myosin
and actin. Physiological dynamic interactions of MyBP-C
with myosin and actin are possible as the distance between
thick and thin ﬁlaments is ∼9–16nm [74] and the length
of extended MyBP-C is ∼40nm [75]. Therefore, MyBP-C is
capabletospantheinterﬁlamentspace,enablinginteractions
with both actin and myosin ﬁlaments.
It is not without precedence that regulation of con-
tractility occurs through dynamic interactions with both
actin and myosin ﬁlaments, as the essential and regulatory
light chains bind tightly to myosin, but also interact with
actin [25, 76, 77]. Additionally, twitchin, a protein similar
to titin, characterized in C. elegans as a thick ﬁlament
regulatory protein, interacts with both myosin and actin in
a phosphorylation-dependent manner to modulate cross-
bridges formation [78, 79]. However, current models (as
described above) to explain the mechanism of contractile
regulation through dynamic binding to myosin and actin
are lacking. Undoubtedly, more work is necessary in order
to understand the precise mechanisms by which MyBP-C
modulates contractility.
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